Time limits apply. Find out if you still qualify.
Verified against court and regulatory records · No upfront fees · Your information is never sold
Qualification
Do You Qualify?
Eligibility checklist
- Used Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, or another GLP-1 receptor agonist
- Developed gastroparesis (stomach paralysis), bowel obstruction, pancreatitis, gallbladder disease, or NAION (vision loss)
- The condition was diagnosed after starting GLP-1 drug therapy
- You have medical records documenting the diagnosis and treatment
- Your claim falls within your state's statute of limitations
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Free · Confidential · About 2 minutes · A case specialist responds within 1 business day
Your answers are never sold or shared without your consent.
The Wire
Latest in this litigation
- July 2026Sharp Rise in Public Search Interest for Ozempic Lawsuits and Side EffectsGoogle Trends data recorded large week-over-week increases in searches for terms including "ozempic lawsuit 2025," "ozempic recall 2025," "ozempic news," and "tirzepatide side effects," with some terms rising several hundred percent and one search ("what is ozempic 2.0") marked as a breakout term.
- July 2026Search Interest in Ozempic Side Effects and Lawsuits SurgesGoogle Trends data recorded sharp week-over-week increases in searches for terms including "ozempic news" (up 2100%), "ozempic lawsuit 2025" (up 550%), "ozempic recall 2025" (up 500%), and "tirzepatide side effects" (up 500%), signaling heightened public interest in Ozempic-related legal and safety topics.
- July 2026FDA Issues Class I Recall for Omnipod 5 Insulin Pods Over Leak RiskThe FDA posted a Class I recall for specific Omnipod 5 pod models manufactured by Insulet Corporation. According to the recall notice, a manufacturing defect can damage the external soft cannula, causing insulin to leak around the pod rather than being delivered to the user. The FDA noted that failure to deliver insulin properly could lead to serious health consequences.
- Full case timeline ↓
How it causes harm
How GLP-1 Drugs Cause Severe Gastrointestinal Injuries
In plain language
GLP-1 receptor agonists produce their weight-loss and blood-sugar effects by dramatically slowing gastric emptying. In a significant subset of patients, this slowing becomes pathological, leading to gastroparesis, bowel obstruction, and other severe conditions.
Gastroparesis (Stomach Paralysis)
GLP-1 drugs activate receptors in the stomach that suppress gastric motility. In susceptible patients, the suppression becomes severe enough to cause gastroparesis — a condition where the stomach cannot empty food normally. Symptoms include severe nausea, vomiting, abdominal pain, bloating, and malnutrition. The condition may persist even after discontinuing the drug.
Intestinal Obstruction / Ileus
The motility-suppressing effects of GLP-1 agonists extend beyond the stomach to the small and large intestine. Severe slowing can cause ileus (intestinal shutdown) or mechanical bowel obstruction, which can be life-threatening and may require emergency surgery.
Pancreatitis
GLP-1 receptors are present on pancreatic acinar cells. Overstimulation may trigger acute pancreatitis — inflammation of the pancreas that causes severe abdominal pain, nausea, and in severe cases organ failure. The JAMA 2023 study found a 9.09x increased risk.
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
GLP-1 drugs may cause sudden, painless vision loss by reducing blood flow to the optic nerve. Studies show semaglutide users face 4-8x higher NAION risk. The mechanism may involve rapid weight loss affecting vascular perfusion or direct vascular effects of GLP-1 receptor activation.
Danger factors
- Patients using GLP-1 drugs for weight loss (off-label or approved) rather than diabetes
- Higher doses used for weight management (Wegovy 2.4mg vs Ozempic 1mg)
- Rapid dose escalation without adequate monitoring
- Patients with pre-existing GI conditions or prior abdominal surgery
- Concurrent use of other medications that slow gastric motility
Scientific consensus
- JAMA 2023 study established statistically significant GI risk elevations (gastroparesis HR 3.67, bowel obstruction HR 4.22)
- FDA updated Ozempic label in September 2023 (ileus) and January 2025 (gastroparesis warning)
- EMA required NAION warnings on European labels in August 2024
- Phase 3 trials showed 82.2% GI adverse event rate vs 53.9% placebo
Why this matters for your case
The harm mechanism evidence supports failure-to-warn claims: the GI risks were known or knowable from clinical trial data and post-market surveillance, yet the manufacturers failed to update labels to warn about gastroparesis specifically until January 2025 — years after millions of prescriptions.
Injured? Get a free Ozempic / GLP-1 Lawsuits case review.
How GLP-1 Drugs Damage the Digestive System
GLP-1 receptor agonists work by mimicking a natural hormone (glucagon-like peptide-1) that regulates blood sugar and appetite. A key mechanism is the dramatic slowing of gastric emptying — the rate at which food moves from the stomach into the small intestine. While this slowing produces the appetite-suppressing and blood-sugar-lowering effects that make these drugs effective, in a significant subset of patients the slowing becomes pathological, resulting in gastroparesis (stomach paralysis) where the stomach cannot empty food normally.
Gastroparesis: A Potentially Permanent Condition
Gastroparesis causes severe nausea, vomiting, abdominal pain, bloating, malnutrition, and dangerous blood sugar fluctuations. In severe cases, patients require hospitalization, nasogastric tubes, total parenteral nutrition (IV feeding), or surgical intervention including gastric electrical stimulator implantation. Critically, the condition may not resolve after discontinuing the drug — some patients report persistent gastroparesis months or years after stopping GLP-1 therapy.
The NAION Crisis
Non-arteritic anterior ischemic optic neuropathy (NAION) is a form of sudden, painless vision loss caused by inadequate blood flow to the optic nerve. A July 2024 JAMA Ophthalmology study found that semaglutide users had 8.9% risk of NAION compared to 1.8% for non-semaglutide users among diabetic patients, and 6.7% vs 0.8% among weight-loss patients. A Danish/Norwegian cohort study of 424,000+ patients confirmed the finding. Despite this evidence and EMA action requiring European label updates, Novo Nordisk has not updated U.S. labels.
The Clinical Trial Evidence Gap
Phase 3 clinical trials for semaglutide showed that 82.2% of patients experienced GI adverse events compared to 53.9% on placebo. However, the trials used definitions and reporting methodologies that may have understated the severity and permanence of gastroparesis. Post-market surveillance through the FDA's FAERS system revealed a pattern of severe gastroparesis, ileus, intestinal obstruction, and fatal complications that was not adequately reflected in pre-approval data.
The Failure-to-Warn Theory
The central legal theory in the GLP-1 litigation is that Novo Nordisk and Eli Lilly failed to provide adequate warnings about gastroparesis and other severe GI complications. Before January 2025, Ozempic's label did not mention gastroparesis by name. The drugs' labels described common side effects (nausea, vomiting, diarrhea) without adequately warning that these could represent the onset of a serious, potentially permanent condition. The EMA's August 2024 decision to require NAION warnings in Europe — while no equivalent U.S. warning exists — further supports the failure-to-warn argument.
MDL Procedure and Bellwether Trials
MDL 3094 consolidates all federal GI injury cases before Judge Karen S. Marston in the Eastern District of Pennsylvania. Fact discovery closed in October 2025, with expert discovery closing in March 2026. Bellwether trial selection will test representative cases to establish settlement value ranges. An August 2025 ruling requiring plaintiffs to have confirmed gastric emptying studies at diagnosis may narrow the plaintiff pool but strengthen remaining claims.
Exposure profiles
GLP-1 Drug Injury Risk Profiles
The risk and type of injury from GLP-1 drugs varies based on the specific drug, dosage, duration of use, and whether the drug was prescribed for diabetes or weight loss.
Weight-Loss Patient (Highest Litigation Volume)
High riskSemaglutide or Tirzepatide for Weight Loss
Common tasks
- Prescribed Wegovy (semaglutide 2.4mg) or Zepbound (tirzepatide) for obesity/overweight
- Used Ozempic or Mounjaro off-label for weight loss
- Developed gastroparesis, bowel obstruction, or pancreatitis during treatment
Diabetic Patient with Severe GI Injury
Moderate riskSemaglutide or Tirzepatide for Type 2 Diabetes
Common tasks
- Prescribed Ozempic, Rybelsus, or Mounjaro for type 2 diabetes
- Developed gastroparesis requiring hospitalization or surgical intervention
- Experienced bowel obstruction or severe pancreatitis
NAION / Vision Loss Patient
High riskSemaglutide Use with Vision Loss
Common tasks
- Experienced sudden, painless vision loss in one or both eyes while on semaglutide
- Diagnosed with NAION (non-arteritic anterior ischemic optic neuropathy)
- Vision loss occurred within months of starting or dose-escalating semaglutide
Each case is evaluated individually. The strength of a claim depends on your specific drug, dosage, timeline, diagnosis, and medical history. Consult an attorney for a case-specific evaluation.
Settlement structure
Ozempic / GLP-1 Lawsuit Projected Settlement Tiers
No GLP-1 trials have concluded yet. Projected values are based on comparable pharmaceutical mass tort outcomes, the severity of injuries, and the strength of the failure-to-warn evidence.
Tier 1 — Mild Gastroparesis, Resolved
SignificantSettlement range
$150,000avg
$100,000 – $250,000
Criteria
- Diagnosed with gastroparesis after GLP-1 use
- Condition resolved or significantly improved after drug discontinuation
- Minimal hospitalization
- Moderate economic damages
Tier 2 — Severe GI Injury or Persistent Gastroparesis
SevereSettlement range
$400,000avg
$250,000 – $700,000
Criteria
- Severe gastroparesis requiring hospitalization, tube feeding, or surgical intervention
- Bowel obstruction requiring emergency surgery
- Acute pancreatitis with hospitalization
- Condition persists after drug discontinuation
Tier 3 — NAION, Fatal Outcome, or Catastrophic Injury
CatastrophicSettlement range
$1,000,000avg
$700,000 – $1,500,000
Criteria
- NAION with permanent vision loss
- Death from GI complications (bowel obstruction, pancreatitis)
- Permanent gastroparesis requiring long-term medical devices
- Multiple severe complications
These are projected ranges based on comparable mass tort outcomes. Actual settlement values will be informed by bellwether trial outcomes expected in 2026. Individual values depend on case-specific facts.
Filing deadlines
Ozempic / GLP-1 Lawsuit Filing Deadlines
The statute of limitations for GLP-1 drug injury claims is typically triggered by the diagnosis of the injury — not by when you started taking the drug. The discovery rule applies in most states.
The Diagnosis-Based Discovery Rule
For pharmaceutical injury claims, most states start the SOL clock when the patient is diagnosed with the condition (gastroparesis, NAION, etc.) or when they knew or should have known that the drug caused their condition. Given that gastroparesis and NAION were not widely known side effects of GLP-1 drugs until the 2023-2024 scientific publications, the discovery rule may extend filing deadlines for patients who were injured before these risks became public knowledge.
Real-World Examples
A woman in California developed gastroparesis in 2023 after using Wegovy for weight loss.
California's 2-year SOL from discovery applies. She likely became aware of the connection to her GLP-1 medication after the October 2023 JAMA study. Her SOL likely runs from late 2023 or early 2024 when the connection became publicly known.
A man in Pennsylvania was diagnosed with NAION in 2024 while taking Ozempic.
Pennsylvania's 2-year SOL from injury/discovery applies. As the MDL home state, Pennsylvania courts are familiar with GLP-1 claims. He should file by 2026 to be safe.
A woman in Florida developed severe pancreatitis in 2022 after Mounjaro.
Florida has a 4-year products liability SOL. She has until approximately 2026-2027 to file, depending on when she discovered the drug connection. Florida's longer SOL is favorable.
Bottom line
If you were diagnosed with gastroparesis, bowel obstruction, pancreatitis, gallbladder disease, or NAION while taking or after taking an Ozempic-class drug, contact an attorney immediately. The SOL clock may be running.
Injured? Get a free Ozempic / GLP-1 Lawsuits case review.
Internal documents
Internal Documents & Evidence
JAMA Study: GLP-1 Agonists Linked to Gastroparesis, Bowel Obstruction, Pancreatitis
From the record
Landmark study analyzing 16 million patient records found GLP-1 agonist users had 3.67x risk of gastroparesis, 4.22x risk of bowel obstruction, and 9.09x risk of pancreatitis compared to patients using bupropion-naltrexone for weight loss.
ImpactBecame the foundational study for the MDL litigation. Directly contradicted manufacturers' characterization of GI side effects as mild and transient.
FDA Label Updates: Ileus and Gastroparesis Warnings Added
From the record
FDA updated Ozempic's label in September 2023 to add ileus warning, then in January 2025 to state the drug is "not recommended in patients with severe gastroparesis." These updates came years after millions of patients had already been prescribed the drug without adequate gastroparesis warnings.
ImpactThe delayed label updates are central to plaintiffs' failure-to-warn theory — the risk was knowable from clinical trial data but not adequately communicated to patients or prescribers.
JAMA Ophthalmology: Semaglutide Linked to Vision Loss (NAION)
From the record
Study found diabetic semaglutide users had 8.9% NAION risk vs 1.8% for non-semaglutide users; weight-loss patients had 6.7% vs 0.8%. A Danish/Norwegian cohort study of 424,000+ patients confirmed semaglutide more than doubled NAION risk.
ImpactPrompted the EMA to require NAION warnings on European labels in August 2024. Novo Nordisk has not updated U.S. labels — a key failure-to-warn argument in the NAION MDL.
Phase 3 Clinical Trial Data: 82% GI Adverse Event Rate
From the record
Novo Nordisk's own Phase 3 trials showed 82.2% of semaglutide patients experienced gastrointestinal adverse events compared to 53.9% on placebo. Severe GI events occurred in 4.1% of Wegovy patients vs 0.9% placebo. These rates were known before FDA approval.
ImpactDemonstrates that Novo Nordisk had pre-market knowledge of significant GI risk, yet the label language described side effects using minimizing terminology.
Regulatory actions
Regulatory Actions on GLP-1 Receptor Agonist Safety
Regulatory agencies have taken incremental action on GLP-1 drug safety, but plaintiffs argue that both the FDA and the manufacturers have been too slow to act given the severity of the adverse events.
Approved Ozempic with Black Box Warning for thyroid C-cell tumors (based on rodent studies). GI side effects listed but gastroparesis not specifically named.
Updated Ozempic label to add ileus (intestinal shutdown) as a post-marketing adverse reaction under Warnings and Precautions.
Required NAION (vision loss) warning added to European semaglutide labels. Novo Nordisk has not added equivalent warning to U.S. labels.
September 2024 hearing with Novo Nordisk CEO on Ozempic/Wegovy pricing. Ozempic costs 9x more in U.S. than Germany.
Updated Ozempic label: "not recommended in patients with severe gastroparesis." Added intestinal obstruction warning. First explicit gastroparesis language on the label.
Key takeaway
The pattern of delayed regulatory action supports plaintiffs' failure-to-warn claims: the risks were known or knowable from clinical trial data and post-market surveillance, yet label updates came years after millions had been prescribed the drugs.
Corporate Impact
Impact on Novo Nordisk and Eli Lilly
The GLP-1 litigation threatens billions in liability for two of the world's most profitable pharmaceutical companies, even as they continue to generate record revenue from the drugs at issue.
Novo Nordisk semaglutide revenue (2024)
$29.3B
70% of total company revenue
Eli Lilly tirzepatide revenue (2024)
$16.5B
36% of total company revenue
Pending MDL cases (GI injuries)
3,191
MDL 3094, E.D. Pennsylvania
Projected litigation liability
$2B+
Before bellwether trials
Timeline: Novo Nordisk / Eli Lilly
Key events on the record
FDA approves Ozempic (semaglutide) for type 2 diabetes
FDA approves Wegovy (semaglutide 2.4mg) for weight loss — sales explode
JAMA study exposes GI injury risks; first lawsuits filed
MDL 3094 established; combined GLP-1 revenue exceeds $40 billion
FDA updates gastroparesis warning; NAION MDL established; 3,100+ cases pending
Growing Regulatory and Public Scrutiny
The GLP-1 litigation coincides with growing public concern about pharmaceutical pricing, marketing practices, and the safety of rapid weight-loss drugs.
- Senate HELP Committee hearing in September 2024 grilled Novo Nordisk CEO on pricing (Ozempic costs 9x more in U.S. than Germany)
- FDA compounding crackdown in February 2025 after resolving semaglutide shortage
- Insurance companies increasingly questioning GLP-1 coverage due to safety concerns
- Social media-driven demand created prescribing pressure that may have outpaced safety monitoring
- European regulators acting faster than FDA on label warnings (NAION)
Key takeaway
The financial stakes are enormous — GLP-1 drugs generate over $40 billion in annual revenue. The litigation threatens billions in liability, but the manufacturers' continued aggressive marketing suggests they have calculated that profits exceed projected litigation costs.
Research & evidence
Scientific Evidence
Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Hathaway JT, Shah MP, Hathaway DB, et al. (2024). JAMA Ophthalmology
Key findings
- Type 2 diabetes patients: 8.9% NAION risk on semaglutide vs 1.8% on non-semaglutide medications
- Weight-loss patients: 6.7% NAION risk vs 0.8% on alternatives
- Risk was highest in first year of use
- Findings confirmed by Danish/Norwegian cohort study of 424,000+ patients
- EMA required European label update; Novo Nordisk has not updated U.S. labels
Risk of Gastrointestinal Adverse Events Associated With GLP-1 Receptor Agonists for Weight Loss
Sodhi M, Rezaeianzadeh R, Kezouh A, Bhatt M (2023). JAMA
Key findings
- Gastroparesis hazard ratio: 3.67 (95% CI 1.15-11.90)
- Bowel obstruction hazard ratio: 4.22 (95% CI 1.02-17.40)
- Pancreatitis hazard ratio: 9.09 (95% CI 1.25-66.00)
- Study population was non-diabetic weight-loss patients — directly relevant to majority of MDL plaintiffs
- Findings were robust across sensitivity analyses
GLP-1 Receptor Agonists and Gallbladder Disease: A Systematic Review of Randomized Controlled Trials
Multiple authors (systematic review) (2024). Clinical Gastroenterology and Hepatology
Key findings
- 37% increased relative risk of gallbladder disease across 76 RCTs
- Risk was more pronounced with higher doses and greater weight loss
- Rapid weight loss mechanism contributes to gallstone formation
- Risk increased with duration of GLP-1 agonist use
- Findings support inclusion of gallbladder disease in GLP-1 litigation claims
Case results
Notable Verdicts & Settlements
$9B
$9,000,000,000
Comparable: Actos (Pioglitazone) Bladder Cancer MDL
Takeda's Actos bladder cancer MDL produced a $9 billion jury verdict (later reduced) — a comparable pharmaceutical failure-to-warn case involving a diabetes drug with cancer risks the manufacturer concealed.
$4.85B
$4,850,000,000
Comparable: Vioxx Cardiovascular MDL
Merck's Vioxx global settlement of $4.85 billion for cardiovascular injuries from a drug with suppressed safety data — the gold standard comparable for pharmaceutical failure-to-warn mass tort settlements.
$775M
$775,000,000
Comparable: Xarelto GI Bleeding MDL
Bayer/J&J settled Xarelto GI bleeding claims for $775 million — a comparable pharmaceutical MDL involving GI side effects of a blockbuster drug.
$300,000 avg
Comparable: Proton Pump Inhibitor (PPI) Kidney MDL
PPI kidney injury settlements averaged $300,000 per claim — a comparable pharmaceutical GI drug mass tort. GLP-1 gastroparesis claims are expected to settle in a similar or higher range.
From the docket
Litigation Timeline
- December 2017
FDA Approves Ozempic for Type 2 Diabetesproduct-launch
FDA approves semaglutide injection (Ozempic) for type 2 diabetes. Label includes thyroid cancer Black Box Warning and GI side effects but does not name gastroparesis.
- June 2021
FDA Approves Wegovy for Weight Lossproduct-launch
FDA approves higher-dose semaglutide (Wegovy 2.4mg) for chronic weight management. Sales explode as social media drives demand for the "skinny shot." Off-label Ozempic prescriptions for weight loss also surge.
- May 2022
FDA Approves Mounjaro (Tirzepatide)product-launch
Eli Lilly's Mounjaro (tirzepatide) approved for type 2 diabetes. Later approved as Zepbound for weight loss in November 2023. The dual GIP/GLP-1 agonist produces even greater weight loss than semaglutide.
- September 2023
FDA Adds Ileus Warning to Ozempic Labelregulatory
FDA updates Ozempic labeling to add ileus as a post-marketing adverse reaction. This is the first official acknowledgment of severe GI motility effects beyond nausea and vomiting.
- October 2023
JAMA Study Exposes GI Injury Risksscientific
Sodhi et al. publish landmark JAMA study finding GLP-1 agonists associated with 3.67x gastroparesis risk, 4.22x bowel obstruction risk, and 9.09x pancreatitis risk among weight-loss patients. Triggers wave of lawsuits.
- February 2024
MDL 3094 Establishedfiling
The JPML consolidates GLP-1 GI injury cases into MDL 3094 in the Eastern District of Pennsylvania before Judge Karen S. Marston. Thousands of cases are transferred.
- July 2024
JAMA Study Links Semaglutide to Vision Lossscientific
JAMA Ophthalmology study finds semaglutide users face dramatically elevated NAION risk (8.9% vs 1.8% in diabetic patients). EMA requires European label update in August 2024; Novo Nordisk does not update U.S. labels.
- January 2025
FDA Updates Ozempic Label for Gastroparesisregulatory
FDA updates Ozempic label to state drug is "not recommended in patients with severe gastroparesis" and adds intestinal obstruction warning — the first explicit gastroparesis language on the label.
- August 2025
Judge Marston Ruling on Gastric Emptying Studiesfiling
MDL judge rules that gastroparesis plaintiffs must have a properly performed gastric emptying study confirming delayed emptying at time of diagnosis. May narrow plaintiff pool but strengthens remaining cases.
- December 2025
NAION Vision-Loss MDL Establishedfiling
JPML establishes MDL 3163 for NAION vision-loss claims against Novo Nordisk. Approximately 29 cases consolidated with rapid growth expected. Expert discovery ongoing in the GI MDL; bellwether trials expected mid-2026.
- June 2026
Search Interest in Ozempic Lawsuits and Recalls Spikes Sharplyfiling
Google Trends data detected on June 24, 2026 shows that searches for terms including 'ozempic lawsuit,' 'ozempic recall 2025,' and 'ozempic news' surged dramatically week-over-week, with some terms reaching breakout status. Search interest in semaglutide side effects also rose notably during the same period.
- June 2026
Ozempic Lawsuit and Recall Searches Spike Sharplyfiling
Google Trends data detected major week-over-week increases in searches related to Ozempic lawsuits, recalls, and side effects around June 24, 2026. Search terms including 'ozempic news' rose 2,050%, 'ozempic lawsuit 2025' rose 1,950%, and 'ozempic recall 2023' rose 1,100%. Terms like 'ozempic lawsuit' and 'ozempic news today' also showed breakout or significant growth.
- July 2026
FDA Issues Class I Recall for Omnipod 5 Insulin Pods Over Leak Riskregulatory
The FDA posted a Class I recall for specific Omnipod 5 pod models manufactured by Insulet Corporation. According to the recall notice, a manufacturing defect can damage the external soft cannula, causing insulin to leak around the pod rather than being delivered to the user. The FDA noted that failure to deliver insulin properly could lead to serious health consequences.
- July 2026
Sharp Rise in Public Search Interest for Ozempic Lawsuits and Side Effectsscientific
Google Trends data recorded large week-over-week increases in searches for terms including "ozempic lawsuit 2025," "ozempic recall 2025," "ozempic news," and "tirzepatide side effects," with some terms rising several hundred percent and one search ("what is ozempic 2.0") marked as a breakout term.
- July 2026
Search Interest in Ozempic Side Effects and Lawsuits Surgesfiling
Google Trends data recorded sharp week-over-week increases in searches for terms including "ozempic news" (up 2100%), "ozempic lawsuit 2025" (up 550%), "ozempic recall 2025" (up 500%), and "tirzepatide side effects" (up 500%), signaling heightened public interest in Ozempic-related legal and safety topics.
Injured? Get a free Ozempic / GLP-1 Lawsuits case review.
Medical condition
Gastroparesis (Stomach Paralysis) from GLP-1 Receptor Agonist Use
Medical definition
Gastroparesis is a condition in which the stomach cannot empty food at a normal rate due to impaired motility. When caused by GLP-1 receptor agonists, the drug's activation of GLP-1 receptors in the stomach suppresses gastric motility to a pathological degree. Unlike diabetic gastroparesis (which develops gradually over years), drug-induced gastroparesis can develop rapidly — within weeks to months of starting the medication.
Symptoms
Severe, persistent nausea
often unresponsive to anti-nausea medications
Vomiting of undigested food hours after eating
Early satiety
feeling full after eating very small amounts
Severe abdominal pain and bloating
Malnutrition and significant unintended weight loss beyond the drug's intended effect
Dangerous blood sugar fluctuations (hypoglycemia and hyperglycemia)
Gastroesophageal reflux and aspiration risk
Bezoar formation (hardened food masses in the stomach)
Risk Factors
- Use of GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, dulaglutide)
- Higher doses (weight-loss doses higher than diabetes doses)
- Rapid dose escalation
- Pre-existing GI conditions (GERD, IBS)
- Prior abdominal surgery
- Concurrent use of opioids or other medications that slow gastric motility
Diagnosis Process
- 01Gastric emptying scintigraphy (4-hour study) — the gold standard diagnostic test
- 02Wireless motility capsule (SmartPill)
- 03Upper endoscopy to rule out mechanical obstruction
- 04CT scan or abdominal imaging to exclude other causes
- 05Review of medication history to establish temporal relationship to GLP-1 drug use
Treatment Options
Prognosis
Prognosis varies significantly. Some patients improve after discontinuing the GLP-1 drug, but recovery may take months. A subset of patients develop persistent gastroparesis that does not resolve after drug discontinuation, requiring long-term management. Severe cases may require surgical intervention or permanent dietary modifications.
FAQ
Frequently Asked Questions
Dive deeper
In-Depth Guides
- Ozempic Stomach Paralysis LawsuitGastroparesis — stomach paralysis — is the primary injury in the GLP-1 MDL. Over 3,000 lawsuits allege that Ozempic and similar drugs cause a potentially permanent condition that was not adequately disclosed.
- Ozempic Gallbladder ProblemsGLP-1 drug users face a 37% increased risk of gallbladder disease. Rapid weight loss combined with GLP-1 effects on bile duct motility creates conditions for gallstone formation and cholecystitis.
- Ozempic Pancreatitis LawsuitThe JAMA 2023 study found a 9.09x increased risk of pancreatitis among GLP-1 users for weight loss. Acute pancreatitis can be life-threatening and requires hospitalization.
- Ozempic Bowel ObstructionGLP-1 drugs slow motility throughout the entire GI tract, not just the stomach. Severe slowing can cause ileus or mechanical bowel obstruction — life-threatening emergencies that may require surgery.
- Ozempic Vision Loss (NAION)Studies show semaglutide users face 4-8x higher risk of NAION — sudden, painless, permanent vision loss. The EMA required European warnings in 2024, but U.S. labels still do not include a NAION warning.
- Ozempic Settlement AmountsNo GLP-1 trials have concluded yet, but projected settlements based on comparable pharmaceutical mass torts suggest $100,000 to $1.5 million+ depending on injury severity.
- Novo Nordisk GLP-1 LawsuitNovo Nordisk generated $29.3 billion in semaglutide revenue in 2024 while allegedly failing to warn about severe side effects. The company's aggressive marketing and delayed label updates are central to the litigation.
- Ozempic, Wegovy & Mounjaro LawsuitsThe GLP-1 MDL consolidates claims against both Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound). All semaglutide and tirzepatide products are at issue.
Deadlines & venues
Deadlines & Venues by State
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Keep reading
Explore This Litigation
Stay informed
Get free updates on the Ozempic / GLP-1 litigation as it develops
No phone call required. We will email you when there is meaningful news — new filings, settlements, or important deadlines.
Sources & References
- Sodhi M, et al. Risk of Gastrointestinal Adverse Events Associated With GLP-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-1797. — JAMA (October 2023)
- Hathaway JT, et al. Risk of NAION in Semaglutide Users. JAMA Ophthalmology. 2024. — JAMA Ophthalmology (July 2024)
- MDL 3094 — In Re: GLP-1 RAs Products Liability Litigation — E.D. Pennsylvania
- Senate HELP Committee Hearing on Ozempic/Wegovy Pricing — U.S. Senate (September 2024)